Zika Virus Infection With Prolonged Maternal Viremia and Fetal Brain Abnormalities

Driggers, Rita W.; Ho, Cheng Ying; Korhonen, Essi M.; Kuivanen, Suvi; Jääskeläinen, Anne J.; Smura, Teemu; Rosenberg, Alex; Hill, Denis; DeBiasi, Roberta L.; Vézina, Gilbert; Timofeev, Julia; Rodríguez, Felipe; Levanov, Lev; Razak, Jennifer; Iyengar, Preetha; Hennenfent, Andrew K.; Kennedy, Rebecca A.; Lanciotti, Robert S.; Plessis, Adré du; Vapalahti, Olli

doi:10.1097/01.aoa.0000512046.09676.84

Cited by 189 publications

(309 citation statements)

References 0 publications

Supporting

Mentioning

279

Contrasting

Unclassified

Order By: Relevance

“…HSV-1 was amplified in Vero cells, as described previously (Nygardas et al, 2013). ZIKV FB-GWUH-2016 strain was cultured in Vero E6 cells, as described earlier (Driggers et al, 2016).…”

Section: Virusesmentioning

confidence: 99%

Novel activities of safe-in-human broad-spectrum antiviral agents

et al. 2018

View full text Add to dashboard Cite

According to the WHO, there is an urgent need for better control of viral diseases. Re-positioning existing safe-in-human antiviral agents from one viral disease to another could play a pivotal role in this process. Here, we reviewed all approved, investigational and experimental antiviral agents, which are safe in man, and identified 59 compounds that target at least three viral diseases. We tested 55 of these compounds against eight different RNA and DNA viruses. We found novel activities for dalbavancin against echovirus 1, ezetimibe against human immunodeficiency virus 1 and Zika virus, as well as azacitidine, cyclosporine, minocycline, oritavancin and ritonavir against Rift valley fever virus. Thus, the spectrum of antiviral activities of existing antiviral agents could be expanded towards other viral diseases.

show abstract

“…HSV-1 was amplified in Vero cells, as described previously (Nygardas et al, 2013). ZIKV FB-GWUH-2016 strain was cultured in Vero E6 cells, as described earlier (Driggers et al, 2016).…”

Section: Virusesmentioning

confidence: 99%

Novel activities of safe-in-human broad-spectrum antiviral agents

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Next, we analyzed whether CLR01 was active against epidemic ZIKV strains. The FB-GWUH-2016 isolate was derived in 2016 from the fetus of a pregnant Finnish tourist returning from South America (Driggers et al, 2016), and the PRVABC-59 isolate represents the current American epidemic strain, isolated in 2015 from a Puerto Rican patient (Lanciotti et al, 2016). Both ZIKV strains were exposed to CLR01 upon infection of Vero E6 cells.…”

Section: Clr01 Blocks Clinically Relevant Zikv Strainsmentioning

confidence: 99%

The molecular tweezer CLR01 inhibits Ebola and Zika virus infection

et al. 2018

View full text Add to dashboard Cite

Ebola (EBOV) and Zika viruses (ZIKV) are responsible for recent global health threats. As no preventive vaccines or antiviral drugs against these two re-emerging pathogens are available, we evaluated whether the molecular tweezer CLR01 may inhibit EBOV and ZIKV infection. This small molecule has previously been shown to inactivate HIV-1 and herpes viruses through a selective interaction with lipid-raft-rich regions in the viral envelope, which results in membrane disruption and loss of infectivity. We found that CLR01 indeed blocked infection of EBOV and ZIKV in a dose-dependent manner. The tweezer inhibited infection of epidemic ZIKV strains in cells derived from the anogenital tract and the central nervous system, and remained antivirally active in the presence of semen, saliva, urine and cerebrospinal fluid. Our findings show that CLR01 is a broad-spectrum inhibitor of enveloped viruses with prospects as a preventative microbicide or antiviral agent.

show abstract

“…In these recent outbreaks outside of Africa, transmission is believed to be primarily a human-mosquitohuman cycle with A. aegypti as the primary mosquito vector [116]. However, non-vector-borne modes of transmission have been reported: sexual [117][118][119][120][121][122][123][124][125][126][127][128][129][130][131][132][133] including male to male [134] and female to male [135], perinatal and intrauterine [136][137][138][139][140][141][142][143][144], breast feeding [136,144,145] and blood transfusion [43,[146][147][148][149].…”

Section: Zika Virus As a Global Public Health Concernmentioning

confidence: 99%

Emerging Infectious Diseases and Blood Safety: Modeling the Transfusion-Transmission Risk

Kiely

Gambhir

Cheng

et al. 2017

Transfusion Medicine Reviews

View full text Add to dashboard Cite

While the transfusion-transmission (TT) risk associated with the major transfusion-relevant viruses such as HIV is now very low, during the last 20 years there has been a growing awareness of the threat to blood safety from emerging infectious diseases, a number of which are known to be, or are potentially, transfusion transmissible. Two published models for estimating the transfusion-transmission risk from EIDs, referred to as the Biggerstaff-Petersen model and the European Upfront Risk Assessment Tool (EUFRAT), respectively, have been applied to several EIDs in outbreak situations. We describe and compare the methodological principles of both models, highlighting their similarities and differences. We also discuss the appropriateness of comparing results from the two models. Quantitating the TT risk of EIDs can inform decisions about risk mitigation strategies and their cost-effectiveness. Finally, we present a qualitative risk assessment for Zika virus (ZIKV), an EID agent that has caused several outbreaks since 2007. In the latest and largest ever outbreak, several probable cases of transfusion-transmission ZIKV have been reported, indicating that it is transfusion-transmissible and therefore a risk to blood safety. We discuss why quantitative modeling the TT risk of ZIKV is currently problematic.

show abstract

Zika Virus Infection With Prolonged Maternal Viremia and Fetal Brain Abnormalities

Cited by 189 publications

References 0 publications

Novel activities of safe-in-human broad-spectrum antiviral agents

Novel activities of safe-in-human broad-spectrum antiviral agents

The molecular tweezer CLR01 inhibits Ebola and Zika virus infection

Emerging Infectious Diseases and Blood Safety: Modeling the Transfusion-Transmission Risk

Contact Info

Product

Resources

About